基于肠促胰岛素的儿童肥胖治疗机制与方案研究

本研究重点阐述了肠促胰岛素（特别是胰高血糖素样肽-1（GLP-1））在内分泌疾病跨学科治疗中日益重要的作用。GLP-1通过影响碳水化合物代谢、胰岛素分泌及其他代谢过程发挥疗效。文章系统描述了这类肽类物质的分泌机制、生物活性及降解过程，并阐明其在调节食欲、胃肠蠕动和糖代谢中的关键作用，这些发现为全面理解GLP-1合成类似物的作用效应提供了理论基础。

在儿童青少年肥胖治疗方面，我们探讨了包括利拉鲁肽等GLP-1受体激动剂在内的现代治疗方案。临床研究数据证实，利拉鲁肽能安全有效地降低肥胖儿童体重并改善代谢指，其疗效在12-18岁肥胖青少年中达43.3%-76.5%。治疗使肥胖儿童高血压患病率从30.9%降至4.8%，糖代谢异常率从41.1%降至19.4%，血脂异常率从20.6%降至9.7%。

研究显示，利拉鲁肽除减重作用外，还具有心脏保护效应：通过适度降压、改善血脂、增强内皮功能及抗炎抗氧化作用，可使2型糖尿病合并高心血管风险患者的主要不良心血管事件风险降低13%-22%。文章进一步探讨了GLP-1受体激动剂在心血管领域的应用前景，特别是其降低2型糖尿病合并肥胖患者心血管事件风险的潜在价值。

1. Tsygankova OV, Veretyuk VV, Ametov AS. Inkretiny segodnya: mnozhestvennye effekty i terapevticheskii potentsial. Sakharnyi diabet. / Tsygankova OV, Veretyuk VV, Ametov AS. Incretins today: multiple effects and therapeutic potential. Diabetes Mellitus. 2019;22(1):70-78. https://doi.org/10.14341/dm9841. (In Russ.).

2. Demidova TYu, Lobanova KG, Oinotkinova OSh. Kishechnaya mikrobiota kak endokrinnyi organ. Ozhirenie i metabolizm. / Demidova TY, Lobanova KG, Oynotkinova OS. Gut microbiota is an endocrine organ. Obesity and Metabolism. 2020;17(3):299-306. https://doi.org/10.14341/omet12457. (In Russ.).

3. Gautier J, Fetita S, Sobngwi E, Salaün-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes & Metabolism. 2005;31(3):233-242. https://doi.org/10.1016/s1262-3636(07)70190-8.

4. Drucker DJ. MiniReview: The Glucagon-Like Peptides. Endocrinology. 2001;142(2):521-527. https://doi.org/10.1210/endo.142.2.7983.

5. Zhang X, Young RL, Bound M, et al. Comparative effects of proximal and distal small intestinal glucose exposure on glycemia, incretin hormone secretion, and the incretin effect in health and type 2 diabetes. Diabetes Care. 2019;42(4):520-528. https://doi.org/10.2337/dc18-2156.

6. Kim EI, Ershova EV, Mazurina NV, Komshilova KA. Postbariatricheskie gipoglikemii: vzglyad endokrinologa. Ozhirenie i metabolizm. / Kim EI, Ershova EV, Mazurina NV, Komshilova KA. A view at postbariatric hypoglycemia by endocrinologist. Obesity and Metabolism. 2022;18(4):471-483. https://doi.org/10.14341/omet12785. (In Russ.).

7. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagonlike peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565. https://doi.org/10.2337/db10-0474.

8. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):14091439. https://doi.org/10.1152/physrev.00034.2006.

9. Peterkova VA, Bezlepkina OB, Bolotova NV, i soavt. Klinicheskie rekomendatsii «Ozhirenie u detei». Problemy endokrinologii. / Peterkova VA, Bezlepkina OB, Bolotova NV, et al. Clinical guidelines «Obesity in children». Problems of Endocrinology. 2021;67(5):67-83. https://doi.org/10.14341/probl12802. (In Russ.).

10. Johnson VR, Washington TB, Chhabria S, et al. Food as medicine for obesity treatment and management. Clin Ther. 2022;44(5):671-681. https://doi.org/10.1016/J.CLINTHERA.2022.05.001.

11. Nicolucci A, Maffeis C. The adolescent with obesity: what perspectives for treatment? Ital J Pediatr. 2022;48(1). https://doi.org/10.1186/S13052-022-01205-W.

12. Smith JD, Fu E, Kobayashi MA. Prevention and Management of Childhood Obesity and Its Psychological and Health Comorbidities. Annu Rev Clin Psychol. 2020 May 7;16:351-378. https://doi.org/10.1146/annurev-clinpsy-100219-060201.

13. Kim A, Nguyen J, Babaei M, Kim A, Geller DH, Vidmar AP. A Narrative review: Phentermine and topiramate for the Treatment of Pediatric Obesity. Adolescent Health Medicine and Therapeutics. 2023;Volume 14:125-140. https://doi.org/10.2147/ahmt.s383454.

14. Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, Mastrandrea LD, Prabhu N, Arslanian S; NN8022-4180 Trial Investigators. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020 May 28;382(22):2117-2128. https://doi.org/10.1056/NEJMoa1916038.

15. Vitebskaya AV, Popovich AV. Opyt primeneniya liraglutida u podrostkov s prostym ozhireniem i soputstvuyushchimi zabolevaniyami zheludochno-kishechnogo trakta. Ozhirenie i metabolizm. / Vitebskaya AV, Popovich AV. Liraglutide in adolescents with simple obesity and gastrointestinal comorbidities: treatment experience. Obesity and metabolism. 2023;20(2):124-130. https://doi.org/10.14341/omet12922. (In Russ.).

16. Sharshova OG, Chubarov TV, Peterkova VA, Zhdanova OA, Artyushchenko AI. Effek tivnost' i bezopasnost' primeneniya liraglutida v terapii detskogo ozhireniya. Vestnik Rossiiskoi akademii meditsinskikh nauk. / Sharshova OG, Chubarov TV, Peterkova VA, Zhdanova OA, Artyushchenko AI. Effectiveness and safety of liraglutide in the treatment of childhood obesity. Annals of the Russian Academy of Medical Sciences. 2024;79(6):515-522. https://doi.org/10.15690/vramn18011. (In Russ.).

17. Fox CK, Barrientos-Pérez M, Bomberg EM, Dcruz J, Gies I, Harder-Lauridsen NM, Jalaludin MY, Sahu K, Weimers P, Zueger T, Arslanian S; SCALE Kids Trial Group. Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. N Engl J Med. 2025;392(6):555-565. https://doi.org/10.1056/NEJMoa2407379.

18. Li Y, Rosenblit PD. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect? Curr Cardiol Rep. 2018 Sep 26;20(11):113. https://doi.org/10.1007/s11886-018-1051-2.

19. Gerstein HC, Colhoun HM, Dagenais GR, et al.; REWIND Trial Investigators. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018 Jan;20(1):42-49. https://doi.org/10.1111/dom.13028.

20. Fisher M, Petrie MC, Ambery PD, et al. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol. 2015 Sep;3(9):697-703. https://doi.org/10.1016/S2213-8587(15)00233-8.

21. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. https://doi.org/10.1056/NEJMoa1603827.

22. Helmstädter J, Keppeler K, Aust F, et al. GLP-1 analog liraglutide improves vascular function in polymicrobial sepsis by reduction of oxidative stress and inflammation. Antioxidants. 2021;10(8):1175. https://doi.org/10.3390/antiox10081175.

23. Mehdi SF, Pusapati S, Anwar MS, et al. Glucagon-like peptide-1: a multifaceted anti-inflammatory agent. Frontiers in Immunology. 2023;14. https://doi.org/10.3389/fimmu.2023.1148209.

24. Bendotti G, Montefusco L, Lunati ME, et al. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacological Research. 2022;182:106320. https://doi.org/10.1016/j.phrs.2022.106320.

25. Khalimov YuSh, Agafonov PV, Kuz'mich VG, Salukhov VV. Agonisty retseptorov glyukogonopodobnogo peptida 1 tipa i novye vozmozhnosti pervichnoi profilaktiki serdechno-sosudistykh oslozhnenii u bol'nykh sakharnym diabetom 2 tipa. Doktor. Ru

26. Lu C, Xie T, Guo X, et al. Glucagon-like peptide-1 receptor agonist exendin-4 mitigates lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages. International Immunopharmacology. 2019;77:105969. https://doi.org/10.1016/j.intimp.2019.105969.

27. Diz-Chaves Y, Herrera-Pérez S, González-Matías LC, Mallo F. Effects of Glucagonlike peptide 1 (GLP-1) analogs in the hippocampus. Vitamins and Hormones. January 2022:457-478. https://doi.org/10.1016/bs.vh.2021.12.005.

28. Manavi MA. Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities. Neuropeptides. 2022;94:102250. https://doi.org/10.1016/j.npep.2022.102250.

29. Cheng D, Yang S, Zhao X, Wang G. The role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases. Drug Design Development and Therapy. 2022;Volume 16:665-684. https://doi.org/10.2147/dddt.s348055.

30. Shamkhalova MS, Sklyanik IA, Shestakova MV. Nephroprotective potential of glucagon-like peptide-1 receptor agonists. Diabetes Mellitus. 2020;23(1):56-64. https://doi.org/10.14341/dm12379.

31. Chen J, Zhao H, Ma X, et al. GLP-1/GLP-1R signaling in regulation of adipocyte differentiation and lipogenesis. Cellular Physiology and Biochemistry. 2017;42(3):11651176. https://doi.org/10.1159/000478872.

32. Balteau M, Van Steenbergen A, Timmermans AD, et al. AMPK activation by glucagonlike peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes. AJP Heart and Circulatory Physiology. 2014;307(8):H1120-H1133. https://doi.org/10.1152/ajpheart.00210.2014.

33. Veprik A, Denwood G, Liu D, et al. Acetyl-CoA-carboxylase 1 (ACC1) plays a critical role in glucagon secretion. Communications Biology. 2022;5(1). https://doi.org/10.1038/s42003-022-03170-w.

34. Bu T, Sun Z, Pan Y, Deng X, Yuan G. Glucagon-Like peptide-1: new regulator in lipid metabolism. Diabetes & Metabolism Journal. 2024;48(3):354-372. https://doi.org/10.4093/dmj.2023.0277.

35. Gaspari T, Brdar M, Lee HW, et al. Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis. Diabetes and Vascular Disease Research. 2015;13(1):56-68. https://doi.org/10.1177/1479164115605000.